Grantham, Mayo, Van Otterloo & Co (GMO)
UTHR icon

Grantham, Mayo, Van Otterloo & Co (GMO)’s United Therapeutics UTHR Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.78M Sell
3,277
-175
-5% -$98.6K ﹤0.01% 464
2026
Q1 		$2.05M Buy
3,452
+2,834
+459% +$1.41M 0.01% 431
2025
Q4 		$301K Sell
618
-14,450
-96% -$6.73M ﹤0.01% 613
2025
Q3 		$6.32M Buy
15,068
+6,079
+68% +$2.04M 0.02% 268
2025
Q2 		$2.58M Buy
8,989
+6,467
+256% +$1.93M 0.01% 352
2025
Q1 		$777K Sell
2,522
-5,705
-69% -$1.96M ﹤0.01% 479
2024
Q4 		$2.9M Buy
8,227
+4,139
+101% +$1.52M 0.01% 346
2024
Q3 		$1.46M Sell
4,088
-24,634
-86% -$8.32M ﹤0.01% 397
2024
Q2 		$9.15M Buy
28,722
+21,486
+297% +$5.69M 0.03% 274
2024
Q1 		$1.66M Buy
+7,236
New +$1.63M 0.01% 371
2021
Q3 		– Sell
-2,068
Closed -$371K – 772
2021
Q2 		$371K Sell
2,068
-4,039
-66% -$769K ﹤0.01% 651
2021
Q1 		$1.02M Sell
6,107
-9,100
-60% -$1.52M 0.01% 591
2020
Q4 		$2.31M Sell
15,207
-24,700
-62% -$3.24M 0.01% 417
2020
Q3 		$4.03M Buy
39,907
+34,007
+576% +$3.73M 0.03% 269
2020
Q2 		$714K Sell
5,900
-2,400
-29% -$270K 0.01% 584
2020
Q1 		$787K Buy
+8,300
New +$789K 0.01% 533
2019
Q2 		– Sell
-5,700
Closed -$669K – 777
2019
Q1 		$669K Sell
5,700
-500
-8% -$58.3K ﹤0.01% 541
2018
Q4 		$675K Hold
6,200
– – 0.01% 396
2018
Q3 		$793K Hold
6,200
– – 0.01% 395
2018
Q2 		$702K Buy
6,200
+200
+3% +$22K 0.01% 423
2018
Q1 		$674K Buy
6,000
+3,600
+150% +$457K ﹤0.01% 426
2017
Q4 		$355K Hold
2,400
– – ﹤0.01% 495
2017
Q3 		$281K Hold
2,400
– – ﹤0.01% 489
2017
Q2 		$311K Buy
2,400
+900
+60% +$112K ﹤0.01% 462
2017
Q1 		$203K Buy
+1,500
New +$227K ﹤0.01% 547

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Grantham, Mayo, Van Otterloo & Co (GMO)'s UTHR Position: Q2 2026 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) reduced its United Therapeutics (UTHR) stake by 5.1% in Q2 2026, selling an estimated $98.6K and leaving 3,277 shares worth $1.78M. The position accounts for ﹤0.01% of the portfolio, ranked #464.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in UTHR in Q1 2017 and has held it in 25 quarters since. The position peaked at $9.15M in Q2 2024. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Grantham, Mayo, Van Otterloo & Co (GMO) held 3,277 shares of United Therapeutics worth $1.78M as of Q2 2026.
  • Grantham, Mayo, Van Otterloo & Co (GMO) sold 175 United Therapeutics shares in Q2 2026, an estimated $98.6K.
  • United Therapeutics made up ﹤0.01% of Grantham, Mayo, Van Otterloo & Co (GMO)'s portfolio in Q2 2026, its #464 holding.
  • Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in United Therapeutics in Q1 2017 and has held it in 25 quarters since.
  • Grantham, Mayo, Van Otterloo & Co (GMO)'s United Therapeutics position peaked at $9.15M in Q2 2024.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q2 2026, filed 13 Aug 2026.